Abstract
Metabolički sindrom (MetS) je skup brojnih faktora rizika za nastanak kardiovaskularnih bolesti i dijabetes melitusa tip 2 (DM2). MetS obuhvata amalgam biohemijskih poremećaja: povećan krvni pritisak, šećer u krvi, višak telesne masti oko struka, povećan nivo triglicerida i holesterola. Iako danas postoji više definicija MetS,sa različitim kriterijumima za postavljanje dijagnoze, njegov značaj se ne umanjuje. Rano otkrivanje i adekvatan tretman sprečiće pojavu komplikacija MetS. Cilj ovog rada je da kritički uporedi različite kriterijume za postavljanje dijagnoze MetS imajući u vidu da ne postoji jedinstveni stavovi za definisanje ovog po život opasnog i veoma zastupljenog sindroma.
References
Olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol. 2008; 61(6):697-706.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome―a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006; 23:469–80.
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989; 149:1514–20.
Foster DW. Insulin resistance–a secret killer? N Engl J Med. 1989; 320:733–4.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004; 109:433–8.
Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112:3066– 72.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15:539–53.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16:442–3.
IDF. Worldwide definition of the metabolic syndrome. 2005. http://www.idf.org
Executive summary of The Third Report of The National Cholesterol Education Program (NCEP). . Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–97.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–52.
Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49:403–14.
D’Aiuto FSW, Netuveli G, Donos N, Hingorani AD, Deanfield J, Tsakos G. Association of the metabolic syndrome with severe periodontitis in a large U.S. population-based syrvey. J Clin Endocrinol Metab. 2008; 93:3989–94.
Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor’s clothes fit? Diabetes Care. 2004; 27:1011–2.
Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci. 2002; 967:146–57.
Turban S, Hajduch E. Protein kinase C isoforms: Mediators of reactive lipid metabolites in the development of insulin resistance. FEBS letters. 2011; 585:269–74.
Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008; 1:36–43.
Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009; 117:241– 50.
Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008; 94:206–18.
Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008; 93:s64–s73.
Qi L, Zhang C, van Dam RM, Hu FB. Interleukin-6 genetic variability and adiposity: Associations in two prospective cohorts and systematic review in 26,944 individuals. J Clin Endocrinol Metab. 2007; 92:3618–25.
Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol. 2007; 2:31–56.
Zou C, Shao J. Role of adipocytokines in obesity-associated insulin resistance. J Nutr Biochem. 2008; 19:277–86.
Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006; 116:1813–22.
Houmard JA, Shinebarger MH, Dolan PL, Leggett-Frazier N, Bruner RK, McCammon MR, et al. Exercise training increases GLUT-4 protein concentration in previously sedentary middle-aged men. Am J Physiol. 1993; 264:E896–901.
Dela F, Mikines KJ, von Linstow M, Secher NH, Galbo H. Effect of training on insulin-mediated glucose uptake in human muscle. Am J Physiol. 1992; 263:E1134–43.
Mikines KJ. The influence of physical activity and inactivity on insulin action and secretion in man. Acta Physiol Scand Suppl. 1992; 609:1–43.
Oshida Y, Yamanouchi K, Hayamizu S, Nagasawa J, Ohsawa I, Sato Y. Effects of training and training cessation on insulin action. Int J Sports Med. 1991; 12:484–6.
Ostergard T, Andersen JL, Nyholm B, Lund S, Nair KS, Saltin B, et al. Impact of exercise training on insulin sensitivity, physical fitness, and muscle oxidative capacity in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006; 290:E998–1005.
King DS, Dalsky GP, Clutter WE, Young DA, Staten MA, Cryer PE, et al. Effects of exercise and lack of exercise on insulin sensitivity and responsiveness. J Appl Physiol. 1988; 64:1942–6.
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113:1888–904.
Huang PL. Unraveling the links between diabetes, obesity, and cardiovascular disease. Circ Res. 2005; 96:1129–31.
Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest. 2007; 117:1961–7.